Last reviewed · How we verify
Lidocaïne 2%
Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.
Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Local anesthesia for minor surgical procedures, Topical anesthesia for skin and mucous membranes, Infiltration anesthesia.
At a glance
| Generic name | Lidocaïne 2% |
|---|---|
| Also known as | lignocaïne, Linisol |
| Sponsor | University of Liege |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Lidocaine is a local anesthetic that works by inhibiting sodium influx through voltage-gated sodium channels in the neuronal cell membrane. This prevents depolarization and the generation of action potentials, thereby blocking pain signal transmission along nerves. It is used topically or by injection to produce local anesthesia in specific tissues or regions.
Approved indications
- Local anesthesia for minor surgical procedures
- Topical anesthesia for skin and mucous membranes
- Infiltration anesthesia
Common side effects
- Allergic reactions (rare with amide lidocaine)
- Systemic toxicity (CNS effects: tremor, seizures)
- Cardiovascular effects (hypotension, arrhythmias)
- Local reactions (burning, stinging at injection site)
Key clinical trials
- Use of Ultiva ® Associated With Xylocaine ® in the Procedures of Feticide (PHASE3)
- Fine Needle Aspiration (FNA) Evaluation of the Intrahepatic HBV Reservoir and Its Immunological Characteristics in Chronically HBV-infected Patients (NA)
- Effectiveness of Ketamine Administered by Mesotherapy in Complex Regional Pain Syndrome Type 1 (CRPS1) (PHASE2, PHASE3)
- Benefits of Opioid Free Anesthesia on Morphine Consumption in Gastric Bypass (NA)
- Effectiveness and Safety of STYLAGE® M LIDOCAINE Versus STYLAGE® M in Filling Nasolabial Folds (NA)
- Effectiveness and Safety of STYLAGE® M Lidocaïne for Lips' Volume Augmentation and/or Redefinition of the Outline of the Lips (SMILE) (NA)
- Effectiveness and Safety of STYLAGE® L Lidocaïne in the Treatment of Nasolabial Folds (NA)
- Evaluation of Professional Practices in the Treatment of Refractory Idiopathic Overactive Bladder at the Dose of 50 Units (TOX50IUU)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidocaïne 2% CI brief — competitive landscape report
- Lidocaïne 2% updates RSS · CI watch RSS
- University of Liege portfolio CI